Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Pharmacokinetics of ASP015K: early-phase trial registry
A small indexed set (3 trials) with no open enrollment listed right now.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · none currently recruiting · #5,209 of 28,707 conditions by registered trial count
Pharmacokinetics of ASP015K: 3 US clinical trials tracked, none currently recruiting.
Pharmacokinetics of ASP015K is the subject of 3 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Astellas Pharma Global Development, running 2 of these trials.
Enrollment posture brief
Registry condition pharmacokinetics-of-asp015k
OPEN 0 | RECR 0% | LATE 0 | EARLY 3 | RANK #5209 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Pharmacokinetics of ASP015K has no open enrollment in this registry pull (3 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Pharmacokinetics of ASP015K on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Pharmacokinetics of ASP015K is recruiting below its size-band peers.
0 of 3 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Indexed trials (enrollment closed)
3 total, page 1 of 1
A Phase I Study to Compare 3 Different Strengths of an Extended Release Formulation of ASP015K to an Immediate Release Formulation of ASP015K
Astellas Pharma Global Development
NCT01686217
A Single Oral Dose Study to Compare the Bioavailability Between Two Different Tablet Formulations and Assess if There is a Food Effect With the New Formulation
Astellas Pharma
NCT01484964
A Study to Evaluate the Effect of Verapamil on the Pharmacokinetics of ASP015K in Healthy Adult Subjects
Astellas Pharma Global Development
NCT02111317
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Pharmacokinetics of ASP015K records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Pharmacokinetics of ASP015K trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Pharmacokinetics of ASP015K page
3 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Pharmacokinetics of ASP015K trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Astellas Pharma Global Development sponsors the most Pharmacokinetics of ASP015K trials on record, review their full trial history before evaluating a specific study. See Astellas Pharma Global Development's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Pharmacokinetics of ASP015K condition card totals 3 registered trials; most-linked intervention ASP015K; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.